Goldman Sachs Group Inc Athira Pharma, Inc. Transaction History

Goldman Sachs Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.92 - $2.71 $25,463 - $35,940	-13,262 Reduced 33.11%	26,789 $70,000
Q1 2024 May 15, 2024	BUY	$2.24 - $4.15 $89,714 - $166,211	40,051 New	40,051 $109,000
Q2 2023 May 14, 2024	SELL	$2.36 - $3.59 $264,728 - $402,701	-112,173 Reduced 86.56%	17,416 $51,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $264,728 - $402,701	-112,173 Reduced 86.56%	17,416 $51,000
Q1 2023 May 14, 2024	SELL	$2.26 - $4.22 $91,337 - $170,551	-40,415 Reduced 23.77%	129,589 $323,000
Q1 2023 May 11, 2023	SELL	$2.26 - $4.22 $91,337 - $170,551	-40,415 Reduced 23.77%	129,589 $323,000
Q4 2022 May 14, 2024	BUY	$2.76 - $3.71 $28,439 - $38,227	10,304 Added 6.45%	170,004 $538,000
Q4 2022 Feb 13, 2023	BUY	$2.76 - $3.71 $28,439 - $38,227	10,304 Added 6.45%	170,004 $538,000
Q3 2022 May 14, 2024	SELL	$2.93 - $3.96 $1.23 Million - $1.67 Million	-421,303 Reduced 72.51%	159,700 $474,000
Q3 2022 Nov 10, 2022	SELL	$2.93 - $3.96 $1.23 Million - $1.67 Million	-421,303 Reduced 72.51%	159,700 $0
Q2 2022 May 14, 2024	BUY	$2.74 - $13.43 $1.59 Million - $7.8 Million	581,003 New	581,003 $1.77 Million
Q2 2022 Aug 15, 2022	BUY	$2.74 - $13.43 $1.37 Million - $6.72 Million	500,662 Added 623.17%	581,003 $1.77 Million
Q1 2022 May 16, 2022	SELL	$8.96 - $13.51 $164,012 - $247,300	-18,305 Reduced 18.56%	80,341 $1.08 Million
Q4 2021 Feb 14, 2022	BUY	$9.17 - $16.39 $115,661 - $206,727	12,613 Added 14.66%	98,646 $1.29 Million
Q3 2021 Nov 10, 2021	BUY	$9.15 - $11.09 $787,201 - $954,105	86,033 New	86,033 $807,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.2M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.